Trials / Completed
CompletedNCT00529087
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
A Mulitcenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Malignant Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 460 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with chronic non-malignant pain who have Opioid-Induced Constipation (OIC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N-methylnaltrexone bromide (MOA-728) | Subcutaneous |
| OTHER | placebo | placebo |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-09-14
- Last updated
- 2019-11-25
- Results posted
- 2010-05-11
Locations
78 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00529087. Inclusion in this directory is not an endorsement.